Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners
Tribe Technology set to deliver healthy pipeline of orders from Tier-One minersView Video
Andrada Mining acquisition elevates the miner to emerging mid-tier status
Andrada Mining acquisition elevates the miner to emerging mid-tier statusView Video

Latest Share Chat

Pin to quick picksSanofi Share News (SAN.PA)

Share Price Information for Sanofi (SAN.PA)

Euronext Paris
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 89.94
Bid: 93.35
Ask: 93.36
Change: 0.08 (0.089%)
Spread: 0.01 (0.011%)
Open: 90.23
High: 90.59
Low: 89.73
Prev. Close: 89.86
SAN.PA Live PriceLast checked at -
  • This share is an international stock.

Watchlists are a member only feature

Login to your account

European shares tick higher; Aegon shines on forecast raise

Thu, 11th Aug 2022 17:29

Aug 11 (Reuters) - European shares edged higher on Thursday after a strong rally in the previous session on signs of U.S. inflation cooling, while Aegon climbed after the Dutch insurer raised its full-year forecast.

The pan-European STOXX 600 index rose 0.1%, after clocking its best session in nearly two weeks on Wednesday on bets that a softer-than-expected U.S. inflation reading would encourage the Federal Reserve to become less aggressive on interest rates hikes.

"Even if European stocks are not rallying as some of their counterparts today, they're going up as the interpretation by markets is that the inflation numbers were synonymous with the Fed changing its policy," said Sebastian Paris-Horvitz, head of research at La Banque Postale Asset Management.

Money markets are pricing in over a 60% chance of a 50 bps hike from the Fed at next month's meeting.

Oil stocks led gains as crude prices rose by over 1% after the International Energy Agency raised its oil demand growth forecast for the year.

Healthcare shares led losses, dragged by declines in GSK, Sanofi and Haleon amid growing concerns about U.S. litigation focused on a heartburn drug that contained a probable carcinogen.

Miners also fell 0.8% on weak results from Antofagasta. The company's shares declined 2.2% and dragged peer Rio Tinto down 3.7%.

The STOXX 600 is down about 10% so far this year, compared with a more than 11% decline for Wall Street's S&P 500 index . U.S. equities are heavily dependent on moves in big technology stocks, which fell sharply in the first half of the year on worries over rising interest rates.

"The big decline in global markets in the first quarter was associated with big growth stocks in the U.S. falling, and therefore Europe, which is less heavy on those, outperformed," Paris-Horvitz added.

Still, Europe is struggling with the fallout of the war in Ukraine as it looks to source energy from non-Russian sources.

Germany, often referred to as the European Union's economic engine, is also struggling with scant rainfall. Low water levels on the Rhine, Germany's commercial artery, have disrupted shipping and pushed freight costs up more than five-fold.

Among stocks, Aegon jumped 8.9% after raising forecasts for full-year operating capital generation and 2021-2023 free cash flow. Zurich Insurance Group added 1.7% as it reported a better-than-expected profit gain in the first half.

Siemens gained 0.7%. The engineering group said it continued to see strong industrial demand during its third quarter, but a writedown at Siemens Energy resulted in its first quarterly loss in nearly 12 years.

(Reporting by Shreyashi Sanyal, Anisha Sircar and Johann M Cherian in Bengaluru; Editing by Sriraj Kalluvila and Mike Harrison)

More News
12 Aug 2022 11:00

Drugmakers' shares stabilise after Zantac litigation slump

LONDON, Aug 12 (Reuters) - Shares in GSK, Sanofi , Haleon and Pfizer began to recover on Friday after the companies said that nothing material had changed regarding U.S. litigation focused on heartburn drug Zantac.

Read more
12 Aug 2022 09:01

GSK, Sanofi and Haleon shares stabilise after Zantac litigation slump

LONDON, Aug 12 (Reuters) - Shares in GSK, Sanofi <SASY.PA and Haleon began to stabilise on Friday after the companies said that nothing material had changed regarding U.S. litigation focused on heartburn drug Zantac.

Read more
11 Aug 2022 22:15

GSK, Sanofi and Haleon shares slump on Zantac litigation concerns

LONDON, Aug 11 (Reuters) - Shares in GSK, Sanofi and Haleon fell sharply on Thursday, following declines earlier this week, amid growing investor concerns about U.S. litigation focused on a heartburn drug that contained a probable carcinogen.

Read more
11 Aug 2022 18:45

GSK, Sanofi and Haleon shares slump on Zantac litigation concerns

LONDON, Aug 11 (Reuters) - Shares in GSK, Sanofi and Haleon fell sharply on Thursday, following declines earlier this week, amid growing investor concerns about U.S. litigation focused on a heartburn drug that contained a probable carcinogen.

Read more
11 Aug 2022 12:23

Haleon not a party to U.S. litigation focused on Zantac - spokesperson

LONDON, Aug 11 (Reuters) - Haleon - GSK's recently spun off consumer health unit - is not a party to the U.S. litigation focused on the heartburn medicine Zantac, a spokesperson told Reuters on Thursday.

Read more
10 Aug 2022 17:02

European bourses hold on to U.S. CPI boost

Aug 10 - Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com

EUROPEAN BOURSES HOLD ON TO U.S. CPI BOOST (1150 EDT/1550 GMT)

Read more
9 Aug 2022 16:59

European shares slip with U.S. inflation data in focus

Aug 9 (Reuters) - European shares dipped on Tuesday as investors cautiously waited for key U.S. inflation data later in the week for hints on the Federal Reserve's next move on interest rate increases.

Read more
28 Jul 2022 07:20

Sanofi lifts profit outlook as Dupixent sales surge 43%

July 28 (Reuters) - French healthcare group Sanofi lifted its full-year earnings outlook on continued forecast-beating sales growth for its bestselling drug Dupixent.

Read more
19 Jul 2022 13:00

As COVID patent war rages on, pharma group seeks fairer future access

LONDON, July 19 (Reuters) - An alliance of companies has pledged to ensure equitable access to vaccines and treatments for pandemics, as the friction around intellectual property rights for COVID-19 interventions between the pharmaceutical industry and developing nations endures.

Read more
18 Jul 2022 12:19

GSK's consumer arm Haleon debuts with lacklustre valuation

LONDON, July 18 (Reuters) - British drugmaker GSK spun off its consumer health business on Monday in the biggest listing in Europe for more than a decade, but the unit's market value of 30.5 billion pounds fell well short of the price rival Unilever offered to pay earlier this year.

Read more
7 Jul 2022 15:25

EU drugs regulator open to COVID boosters that target older Omicron offshoots

LONDON, July 7 (Reuters) - The European Medicines Agency (EMA) is open to using next generation COVID-19 vaccines that target older offshoots of the Omicron variant this fall, an official said on Thursday, amid a rise in cases due to new Omicron subvariants.

Read more
24 Jun 2022 17:19

European shares mark strong end to nervous week

June 24 (Reuters) - European stocks jumped 2.6% on Friday, pushing them into positive territory for the week as investors started to scale back central bank tightening bets, spurring inflows into risky assets.

Read more
24 Jun 2022 17:08

Defensive stocks lead rebound in FTSE 100

June 24 (Reuters) - UK's FTSE 100 rose on Friday, lifted by defensive stocks at the end of a choppy week that saw investor anxiety over hawkish central banks, weak economic readings and heightened risks of a global recession.

Read more
24 Jun 2022 09:51

Sanofi, GSK variant-specific COVID shot found effective against Omicron

PARIS/LONDON, June 24 (Reuters) - Late-stage data on an experimental COVID-19 vaccine from Sanofi and GSK has showed the shot confers protection against the Omicron variant of the virus, the companies said on Friday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.